Publications

• Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes.
  Clin Lymphoma Myeloma Leuk
  04/11/2025 Authors: Varga C; Robinson M; Gupta V; Hofmeister CC; Nooka AK; Kaufman JL; Dhodapkar MV; Lonial S; Borden S; Ferreri C
• Persistent opioid use is associated with a shorter myeloma survival.
  Support Care Cancer Volume: 33 Page(s): 374
  04/11/2025 Authors: Sweiss K; Rodriguez AMA; Quigley JG; Sharp L; Kurzweil K; Sweis JG; Calip GS; Hamilton Z; Uzoka C; Ilo E
• Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS.
  Blood Volume: 145 Page(s): 1658 - 1669
  04/10/2025 Authors: Landgren O; Chari A; Cohen YC; Spencer A; Voorhees PM; Sandhu I; Jenner MW; Smith D; Cavo M; van de Donk NWCJ
• Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract.
  Clin Lymphoma Myeloma Leuk
  04/08/2025 Authors: Scott SA; Roberts DL; Gupta VA; Joseph NS; Hofmeister CC; Dhodapkar MV; Lonial S; Nooka AK; Kaufman JL
• Immune-aging is linked to clinical malignancy, racial ancestry and vaccine responses in myeloma.
  Blood Adv
  02/05/2025 Authors: Potdar SV; Kapadia S; Azeem MI; Radzievski R; Lakhani K; Joseph NS; Kaufman JL; Hofmeister CC; Gupta VA; Lonial S
• Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.
  J Hematol Oncol Volume: 18 Page(s): 1
  01/20/2025 Authors: Dona AA; Tandoh T; Nigam L; Singer M; Caserta E; Murtadha M; Zhu Y; Moloudizargari M; Sharma P; Napolitano O
• Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.
  NPJ Vaccines Volume: 9 Page(s): 201
  10/27/2024 Authors: Moreno A; Manning K; Azeem MI; Nooka AK; Ellis M; Manalo RJ; Switchenko JM; Wali B; Kaufman JL; Hofmeister CC
• Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.
  Blood Cancer J Volume: 14 Page(s): 159
  09/13/2024 Authors: Joseph NS; Kaufman JL; Gupta VA; Hofmeister CC; Dhodapkar MV; Boise LH; DiCamillo SM; Roberts D; Nooka AK; Lonial S
• Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience.
  Blood Cancer J Volume: 13 Page(s): 191
  12/20/2023 Authors: Scott SA; Marin EM; Maples KT; Joseph NS; Hofmeister CC; Gupta VA; Dhodapkar MV; Kaufman JL; Lonial S; Nooka AK
• Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
  Oncotarget Volume: 14 Page(s): 837 - 838
  09/25/2023 Authors: Canella A; Nieves HC; Sborov DW; Cascione L; Radomska HS; Smith E; Stiff A; Consiglio J; Caserta E; Rizzotto L
• Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity.
  Res Sq
  09/21/2023 Authors: Moreno A; Manning K; Azeem MI; Nooka AK; Ellis M; Manalo RJ; Switchenko JM; Wali B; Kaufman JL; Hofmeister CC
• Incidence, risk factors and impact of supraventricular tachycardia (SVT) with high dose therapy melphalan among myeloma patients undergoing autologous stem cell transplant (HDT/ASCT)
  Volume: 23 Page(s): S126 - S127
  09/01/2023 Authors: Simon K; Joseph N; Mandawat A; Hofmeister C; Shanmugam M; Kaufman J; Graiser M; Wyman S; Adisa O; Rupji M
• Comparison of a battery powered device (OnControl) versus manual Jamshidi needle for bone marrow biopsy in adult patients with plasma cell disorders: a prospective randomized control trial (RCT)
  Volume: 23 Page(s): S288 - S288
  09/01/2023 Authors: Andrews J; Joseph N; Neely J; Hatcher A; Rosand C; Palmer A; Harrington M; Roberts D; Raine C; Pruitt R
• Maintenance therapy with carfilzomib, pomalidomide and dexamethasone (KPd) in high-risk myeloma patients (pts): a Phase 2 study with a safety run-in
  Volume: 23 Page(s): S119 - S120
  09/01/2023 Authors: Nooka A; Joseph N; Dhodapkar M; Hofmeister C; Gupta V; Andrews J; Gleason C; Burton BJ; Rupji M; McFadden I
• The changing landscape of peri-transplant adverse events with HDT/ASCT and the impact on long term outcomes for myeloma patients
  Volume: 23 Page(s): S129 - S130
  09/01/2023 Authors: Wyman S; Joseph N; Adisa O; Matich T; Behera M; Graiser M; Simon K; Rupji M; Kaufman J; Hofmeister C
• Novel observation of the negative effects of persistent chronic opioid use on myeloma survival: a retrospective urban-based cohort study and ongoing prospective HealthTree survey study
  Volume: 23 Page(s): S306 - S307
  09/01/2023 Authors: Sweiss K; Patel P; Ahlstrom J; Hydren J; Martinez JAH; Rodriguez AMA; Quigley J; Sharp L; Calip G; Rondelli D
• Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients
  Volume: 23 Page(s): S113 - S113
  09/01/2023 Authors: Joseph N; Kaufman J; Lonial S; Hofmeister C; Dhodapkar M; Gupta V; DiCamillo S; Roberts D; Boise L; Nooka A
• Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
  JCO Oncol Pract Volume: 19 Page(s): 793 - 798
  09/01/2023 Authors: Sun LF; Maples KT; Hall KH; Liu Y; Cao Y; Joseph NS; Hofmeister CC; Kaufman JL; Dhodapkar M; Nooka AK
• Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity.
  bioRxiv
  08/22/2023 Authors: Moreno A; Manning K; Azeem MI; Nooka AK; Ellis M; Manalo RJ; Switchenko JM; Wali B; Kaufman JL; Hofmeister CC
• Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.
  J Clin Invest Volume: 133
  08/01/2023 Authors: Robinson MH; Villa NY; Jaye DL; Nooka AK; Duffy A; McCachren SS; Manalo J; Switchenko JM; Barnes S; Potdar S
• PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant.
  Haematologica Volume: 108 Page(s): 2155 - 2166
  08/01/2023 Authors: Thomas M; Li J; King K; Persaud AK; Duah E; Vangundy Z; Hofmeister CC; Lamba JK; Tan AC; Fridley BL
• Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections.
  Blood Cancer Discov Volume: 4 Page(s): 106 - 117
  03/01/2023 Authors: Azeem MI; Nooka AK; Shanmugasundaram U; Cheedarla N; Potdar S; Manalo RJ; Moreno A; Switchenko JM; Cheedarla S; Doxie DB
• Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience.
  Blood Cancer J Volume: 13 Page(s): 29
  02/20/2023 Authors: Maples KT; Hall KH; Joseph NS; Hofmeister CC; Gupta V; Dhodapkar MV; Kaufman JL; Nooka AK; Lonial S
• Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant.
  Cancer Genomics Proteomics Volume: 20 Page(s): 9 - 17
  01/01/2023 Authors: Li J; Cho YK; Sborov DW; Phelps MA; Hofmeister CC; Poi MJ
• CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation.
  Front Pharmacol Volume: 14 Page(s): 1334440
  01/01/2023 Authors: Seligson ND; Zhang X; Zemanek MC; Johnson JA; VanGundy Z; Wang D; Phelps MA; Roddy J; Hofmeister CC; Li J
• Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma.
  Leukemia Volume: 36 Page(s): 2917 - 2921
  12/01/2022 Authors: Slade M; Martin TG; Nathwani N; Fiala MA; Rettig MP; Gao F; Deol A; Buadi FK; Kaufman JL; Hofmeister CC
• Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.
  J Clin Oncol Volume: 40 Page(s): 3057 - 3064
  09/10/2022 Authors: Nooka AK; Shanmugasundaram U; Cheedarla N; Verkerke H; Edara VV; Valanparambil R; Kaufman JL; Hofmeister CC; Joseph NS; Lonial S
• Venetoclax ex vivo functional profiling predicts improved progression-free survival.
  Blood Cancer J Volume: 12 Page(s): 115
  08/04/2022 Authors: Gupta VA; Matulis SM; Barwick BG; Bog RD; Shebelut CW; Shanmugam M; Neri P; Bahlis NJ; Dhodapkar MV; Heffner LT
• The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma.
  Nat Commun Volume: 13 Page(s): 3750
  06/29/2022 Authors: Vo JN; Wu Y-M; Mishler J; Hall S; Mannan R; Wang L; Ning Y; Zhou J; Hopkins AC; Estill JC
• Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.
  Pharmacotherapy Volume: 42 Page(s): 233 - 240
  03/01/2022 Authors: Sivakumar A; Bryson EB; Hall KH; Maples KT; Goyal S; Joseph NS; Hofmeister CC; Kaufman JL; Lonial S; Nooka AK
• Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.
  Transplant Cell Ther Volume: 28 Page(s): 75.e1 - 75.e7
  02/01/2022 Authors: Joseph NS; Gupta VA; Wyman S; Graiser M; Kaufman JL; Almaula D; Andrews J; Hofmeister C; Dhodapkar M; Heffner LT
• A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma.
  Am J Hematol Volume: 97 Page(s): E54 - E58
  02/01/2022 Authors: Cornell RF; Baz R; Richter JR; Rossi A; Vogl DT; Chen C; Shustik C; Alvarez MJ; Shen Y; Unger TJ
• A Single Nucleotide Polymorphism (SNP) in the SLC22A3 Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy.
  Anticancer Res Volume: 42 Page(s): 385 - 395
  01/01/2022 Authors: Li J; Persaud AK; Johnson JA; Sborov DW; Phelps MA; Hofmeister CC; Poi MJ
• Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing.
  Eur J Drug Metab Pharmacokinet Volume: 46 Page(s): 807 - 816
  11/01/2021 Authors: Liva S; Chen M; Mortazavi A; Walker A; Wang J; Dittmar K; Hofmeister C; Coss CC; Phelps MA
• Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.
  Blood Cancer Discov Volume: 2 Page(s): 600 - 615
  11/01/2021 Authors: Kaushal A; Nooka AK; Carr AR; Pendleton KE; Barwick BG; Manalo J; McCachren SS; Gupta VA; Joseph NS; Hofmeister CC
• Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas.
  Laryngoscope Investig Otolaryngol Volume: 6 Page(s): 1008 - 1019
  10/01/2021 Authors: Welling DB; Collier KA; Burns SS; Oblinger JL; Shu E; Miles-Markley BA; Hofmeister CC; Makary MS; Slone HW; Blakeley JO
• Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.
  Blood Volume: 137 Page(s): 3604 - 3615
  07/01/2021 Authors: Gupta VA; Barwick BG; Matulis SM; Shirasaki R; Jaye DL; Keats JJ; Oberlton B; Joseph NS; Hofmeister CC; Heffner LT
• Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma.
  Clin Cancer Res Volume: 27 Page(s): 3178 - 3189
  06/01/2021 Authors: Barwick BG; Gupta VA; Matulis SM; Patton JC; Powell DR; Gu Y; Jaye DL; Conneely KN; Lin YC; Hofmeister CC
• A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
  Cancer Chemother Pharmacol Volume: 87 Page(s): 599 - 611
  05/01/2021 Authors: Collier KA; Valencia H; Newton H; Hade EM; Sborov DW; Cavaliere R; Poi M; Phelps MA; Liva SG; Coss CC
• Oncolytic herpes simplex virus infects myeloma cells invitro and invivo.
  Mol Ther Oncolytics Volume: 20 Page(s): 519 - 531
  03/26/2021 Authors: Ghose J; Dona A; Murtadha M; Gunes EG; Caserta E; Yoo JY; Russell L; Jaime-Ramirez AC; Barwick BG; Gupta VA
• Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
  Am J Hematol Volume: 96 Page(s): E68 - E71
  03/01/2021 Authors: Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH
• Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial.
  Front Immunol Volume: 12 Page(s): 700045
  01/01/2021 Authors: Shindiapina P; Pietrzak M; Seweryn M; McLaughlin E; Zhang X; Makowski M; Ahmed EH; Schlotter S; Pearson R; Kitzler R
• Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.
  Leukemia Volume: 35 Page(s): 189 - 200
  01/01/2021 Authors: Viola D; Dona A; Caserta E; Troadec E; Besi F; McDonald T; Ghoda L; Gunes EG; Sanchez JF; Khalife J
• Downregulation of PA28 induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma.
  Blood Cancer J Volume: 10 Page(s): 125
  12/14/2020 Authors: Gu Y; Barwick BG; Shanmugam M; Hofmeister CC; Kaufman J; Nooka A; Gupta V; Dhodapkar M; Boise LH; Lonial S
• Increased DNA Repair Gene Expression Correlates with MYC Expression and Inferior Progression-Free Survival in Multiple Myeloma Patients
  Volume: 136
  11/05/2020 Authors: Sweiss K; Barwick BG; Calip GS; Rondelli D; Hofmeister CC; Patel P
• Role of clonoSEQ (R), a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma
  Volume: 136
  11/05/2020 Authors: Nooka A; Bradley K; Joseph N; Hofmeister CC; Dhodapkar MV; Boise LH; Lonial S; Li S; Kaufman JL
• Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era
  Volume: 136
  11/05/2020 Authors: Santapuram PR; Rupji M; Graiser M; Waller EK; Blum KA; Allen PB; Koff JL; Heffner L; Lechowicz MJ; Lonial S
• Real World Experience and Patient Satisfaction Surrounding the Implementation of Daratumumab and Hyaluronidase-Fihj in a Large, Academic Medical Center
  Volume: 136
  11/05/2020 Authors: Maples KT; Brechtelsbauer E; Pendexter J; Kaufman JL; Joseph N; Heffner L; Hofmeister CC; Dhodapkar MV; Lonial S; Nooka A
• Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma
  Volume: 136
  11/05/2020 Authors: Barwick BG; Gupta VA; Matulis SM; Patton JC; Powell DR; Gu Y; Jaye DL; Conneely KN; Lin YC; Hofmeister CC
• FIRST-IN-HUMAN PHASE I STUDY OF NKTR-255 IN PATIENTS WITH RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES
  Volume: 8 Page(s): A216 - A217
  11/01/2020 Authors: Shah N; Tan A; Budde L; Hofmeister C; Cowan A; Saeed H; Ye J; Cairo M; Rizzieri D; Orloff G
• Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant.
  Br J Clin Pharmacol Volume: 86 Page(s): 2165 - 2173
  11/01/2020 Authors: Sweiss K; Vemu B; Hofmeister CC; Wenzler E; Calip GS; Galvin JP; Mahmud N; Rondelli D; Johnson JJ; Patel P
• Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation.
  Anticancer Res Volume: 40 Page(s): 5707 - 5713
  10/01/2020 Authors: Li J; Seligson N; Zhang X; Johnson J; Vangundy Z; Wang D; Phelps M; Hofmeister C; Sadee W; Poi MJ
• Characterizing Pain Experiences: African American Patients With Multiple Myeloma Taking Around-the-Clock Opioids.
  Clin J Oncol Nurs Volume: 24 Page(s): 538 - 546
  10/01/2020 Authors: Belcher SM; Watkins Bruner D; Hofmeister CC; Kweon J; Meghani SH; Yeager KA
• Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
  Leukemia Volume: 34 Page(s): 2430 - 2440
  09/01/2020 Authors: Gavriatopoulou M; Chari A; Chen C; Bahlis N; Vogl DT; Jakubowiak A; Dingli D; Cornell RF; Hofmeister CC; Siegel D
• Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
  Volume: 34 Page(s): 1840 - 1852
  07/01/2020 Authors: Landgren CO; Chari A; Cohen YC; Spencer A; Voorhees P; Estell JA; Sandhu I; Jenner MW; Williams C; Cavo M
• Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
  J Clin Oncol Volume: 38 Page(s): 1928 - 1937
  06/10/2020 Authors: Joseph NS; Kaufman JL; Dhodapkar MV; Hofmeister CC; Almaula DK; Heffner LT; Gupta VA; Boise LH; Lonial S; Nooka AK
• Real-world outcomes of venetoclax refractory multiple myeloma patients.
  Volume: 38
  05/20/2020 Authors: Maples KT; Kaufman JL; Gupta VA; Joseph N; Heffner LT; Hofmeister CC; Dhodapkar M; Matulis SM; Boise L; Lonial S
• Efficacy of daratumumab plus SOC versus SOC in myeloma induction regimens, by risk-stratification: Meta-analysis of phase III randomized control trials.
  Volume: 38
  05/20/2020 Authors: Joseph N; Hofmeister CC; Dhodapkar M; Boise L; Lonial S; Behera M; Kaufman JL; Nooka AK
• Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT-CTN-0903/AMC-080 and BMT-CTN-0803/AMC-071 Trials
  Volume: 26 Page(s): S304 - S304
  03/01/2020 Authors: Shindiapina P; Pietrzak M; Seweryn M; McLaughlin E; Zhang X; Makowski M; Lyberger J; Chang H; Ahmed E; Pearson R
• MODELING THROMBOCYTOPENIA AS A PREDICTOR OF OUTCOMES FOLLOWING SINGLE, HIGH DOSE MELPHALAN AND STEM CELL TRANSPLANT IN MULTIPLE MYELOMA.
  Volume: 107 Page(s): S120 - S120
  03/01/2020 Authors: Irby D; Cottini F; Hade E; Hofmeister C; Phelps M
• POPULATION PHARMACOKINETIC (PK) ANALYSIS FROM FIRST-IN-HUMAN DATA FOR HDAC INHIBITOR, REC-2282, IN PATIENTS WITH SOLID TUMORS AND HEMATOLOGIC MALIGNANCIES.
  Volume: 107 Page(s): S97 - S98
  03/01/2020 Authors: Liva S; Mortazavi A; Dittmar K; Walker A; Hofmeister C; Coss C; Phelps M
• MODELING THROMBOCYTOPENIA AS A PREDICTOR OF OUTCOMES FOLLOWING SINGLE, HIGH--DOSE MELPHALAN AND STEM CELL TRANSPLANT IN MULTIPLE MYELOMA.
  Volume: 107 Page(s): S27 - S27
  03/01/2020 Authors: Irby D; Cottini F; Hade E; Hofmeister C; Phelps M
• Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up.
  Biol Blood Marrow Transplant Volume: 26 Page(s): 44 - 49
  01/01/2020 Authors: Sharma N; Chen DT; Zhao Q; Williams NY; Rosko A; Benson DM; Chaudhry M; Bumma N; Khan A; Devarakonda S
• XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant.
  Mol Carcinog Volume: 58 Page(s): 2327 - 2339
  12/01/2019 Authors: Persaud AK; Li J; Johnson JA; Seligson N; Sborov DW; Duah E; Cho YK; Wang D; Phelps MA; Hofmeister CC
• Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
  Blood Cancer J Volume: 9 Page(s): 94
  11/25/2019 Authors: Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J
• The Role of Proteasome Activator PA28 alpha in Multiple Myeloma
  Volume: 134
  11/13/2019 Authors: Gu Y; Barwick BG; Shanmugam M; Hofmeister CC; Kaufman JL; Nooka AK; Gupta VA; Dhodapkar MV; Boise LH; Lonial S
• Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials
  Volume: 134
  11/13/2019 Authors: Shindiapina P; Pietrzak M; Seweryn M; McLaughlin E; Zhang X; Makowski M; Lyberger J; Chang H; Ahmed EH; Prouty A
• Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
  Volume: 134
  11/13/2019 Authors: Bernal-Mizrachi L; Nooka AK; Heffner L; Cole CE; Ye JC; Vij R; Hofmeister CC; Rushton J; Chen Z; Chang Z
• Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma
  Volume: 134
  11/13/2019 Authors: Dona A; Viola D; Caserta E; Besi F; Sanchez JF; Marcucci G; Keats JJ; Krishnan AY; Coffey M; Sborov DW
• MiR-16 regulates crosstalk in NF-B tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages.
  JCI Insight Volume: 4
  11/01/2019 Authors: Khalife J; Ghose J; Martella M; Viola D; Rocci A; Troadec E; Terrazas C; Satoskar AR; Gunes EG; Dona A
• Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization.
  Leuk Res Volume: 85 Page(s): 106215
  10/01/2019 Authors: Andritsos LA; Huang Y; Abraham I; Huff K; Scrape SR; Fan T; Alkhatib N; Hofmeister CC; Drea E; McBride A
• BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas.
  Bone Marrow Transplant Volume: 54 Page(s): 1553 - 1561
  10/01/2019 Authors: Singer S; Sharma N; Dean R; Zhao Q; Abounader D; Elder P; Hofmeister CC; Benson DM; Rosko A; Penza S
• Prevalence and Effect on Engraftment of Residual Disease in Hematopoietic Progenitor Cell Apheresis Collections
  Volume: 59 Page(s): 109A - 110A
  09/01/2019 Authors: Wooten M; Hofmeister CC; Roback JD; Sullivan H
• Daratumumab in multiple myeloma.
  Cancer Volume: 125 Page(s): 2364 - 2382
  07/15/2019 Authors: Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
• Registering a CD38 antibody upfront for multiple myeloma.
  Lancet Volume: 394 Page(s): 3 - 4
  07/06/2019 Authors: Hofmeister CC; Nooka A; Kaufman JL; Lonial S
• Differences in presentation and survival outcomes for African American patients with newly diagnosed multiple myeloma
  Volume: 79
  07/01/2019 Authors: Joseph N; Gupta VA; Hofmeister C; Gleason C; Heffner LT; Jonathan KL; Boise LH; Dhodapkar MD; Lonial S; Nooka AK
• Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
  Eur J Haematol Volume: 102 Page(s): 494 - 503
  06/01/2019 Authors: Dimopoulos MA; Laubach JP; Echeveste Gutierrez MA; Grzasko N; Hofmeister CC; San-Miguel JF; Kumar S; Labotka R; Lu V; Berg D
• Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?
  Bone Marrow Transplant Volume: 54 Page(s): 913 - 916
  06/01/2019 Authors: Vaughn JL; Zhao Q; Epperla N; Puto M; Roddy J; Elder P; Blum W; Klisovic R; Jaglowski S; Penza S
• BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.
  Biol Blood Marrow Transplant Volume: 25 Page(s): 1107 - 1115
  06/01/2019 Authors: Singer S; Dean R; Zhao Q; Sharma N; Abounader D; Elder P; Hofmeister CC; Benson DM; Rosko A; Penza S
• Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant.
  J Geriatr Oncol Volume: 10 Page(s): 479 - 485
  05/01/2019 Authors: Rosko AE; Huang Y; Benson DM; Efebera YA; Hofmeister C; Jaglowski S; Devine S; Bhatt G; Wildes TM; Dyko A
• Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.
  Br J Clin Pharmacol Volume: 85 Page(s): 924 - 934
  05/01/2019 Authors: Hughes JH; Phelps MA; Upton RN; Reuter SE; Gao Y; Byrd JC; Grever MR; Hofmeister CC; Marcucci G; Blum W
• Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
  Nat Commun Volume: 10 Page(s): 1911
  04/23/2019 Authors: Barwick BG; Neri P; Bahlis NJ; Nooka AK; Dhodapkar MV; Jaye DL; Hofmeister CC; Kaufman JL; Gupta VA; Auclair D
• Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
  JCI Insight Volume: 5
  04/23/2019 Authors: Bailur JK; McCachren SS; Doxie DB; Shrestha M; Pendleton K; Nooka AK; Neparidze N; Parker TL; Bar N; Kaufman JL
• Most multiple myeloma patients have low testosterone.
  Leuk Lymphoma Volume: 60 Page(s): 836 - 838
  03/01/2019 Authors: John S; Sharma N; Sborov DW; Williams N; Jones D; Benson DM; Efebera YA; Rosko AE; Vincent J; Hofmeister CC
• Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
  Cancer Volume: 125 Page(s): 416 - 423
  02/01/2019 Authors: Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK
• A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients.
  Anticancer Res Volume: 39 Page(s): 67 - 72
  01/01/2019 Authors: Poi MJ; Li J; Johnson JA; Cho YK; Sborov DW; Phelps MA; Hofmeister CC
• Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT).
  Arch Hematol Blood Dis Volume: 2 Page(s): 12 - 18
  01/01/2019 Authors: Pandit A; Wei L; Bustamante L; Elder P; Falk WBS; Sell M; Rosko A; Benson DM; Devine SM; Hofmeister CC
• Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)
  Volume: 132
  11/29/2018 Authors: Landgren O; Cavo M; Chari A; Cohen YC; Spencer A; Voorhees PM; Estell J; Sandhu I; Jenner M; Williams C
• Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up
  Volume: 132
  11/29/2018 Authors: Sharma N; Williams N; Rosko AE; Benson DM; Chaudhry M; Hofmeister CC; Sborov DW; Efebera Y
• Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial
  Volume: 132
  11/29/2018 Authors: Vij R; Nathwani N; Martin TG; Fiala MA; Deol A; Buadi FK; Kaufman JL; Hofmeister CC; Gregory T; Berdeja JG
• Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant.
  CPT Pharmacometrics Syst Pharmacol Volume: 7 Page(s): 748 - 758
  11/01/2018 Authors: Cho YK; Irby DJ; Li J; Sborov DW; Mould DR; Badawi M; Dauki A; Lamprecht M; Rosko AE; Fernandez S
• Ninety-minute daratumumab infusion is safe in multiple myeloma.
  Leukemia Volume: 32 Page(s): 2495 - 2518
  11/01/2018 Authors: Barr H; Dempsey J; Waller A; Huang Y; Williams N; Sharma N; Benson DM; Rosko AE; Efebera YA; Hofmeister CC
• Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients.
  Bone Marrow Transplant Volume: 53 Page(s): 1418 - 1427
  11/01/2018 Authors: Richardson DR; Huang Y; McGinty HL; Elder P; Newlin J; Kirkendall C; Andritsos L; Benson D; Blum W; Efebera Y
• Modeling of Neutropenia in the Setting of Autologous Stem Cell Transplant with Single, High Dose Chemotherapy and G-CSF
  Volume: 45 Page(s): S43 - S43
  10/01/2018 Authors: Irby DJ; Cho YK; Badawi M; Dauki A; Hofmeister CC; Mould DR; Phelps MA
• Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
  Leukemia Volume: 32 Page(s): 2305
  10/01/2018 Authors: Richardson PG; Hofmeister CC; Raje NS; Siegel DS; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J
• Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.
  Br J Haematol Volume: 182 Page(s): 231 - 244
  07/01/2018 Authors: Richardson PG; Hofmeister CC; Rosenbaum CA; Htut M; Vesole DH; Berdeja JG; Liedtke M; Chari A; Smith SD; Lebovic D
• Impact of individual comorbidities on post-transplant outcomes for elderly patients with non-Hodgkin lymphoma (NHL).
  Volume: 36
  05/20/2018 Authors: Ip A; Switchenko JM; Graiser M; Koff JL; Gupta VA; Lechowicz MJ; Nooka AK; Kaufman JL; Lonial S; Waller EK
• Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction.
  Volume: 36
  05/20/2018 Authors: Harvey RD; Kaufman JL; Heffner LT; Hofmeister CC; Dhodapkar MV; Lonial S; Nooka AK
• A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF DARATUMUMAB MONOTHERAPY FOR PATIENTS (PTS) WITH INTERMEDIATE OR HIGH-RISK SMOLDERING MULTIPLE MYELOMA (SMM): CENTAURUS
  Volume: 103 Page(s): 40 - 41
  04/18/2018 Authors: Cavo M; Hofmeister CC; Chari A; Cohen YC; Spencer A; Voorhees P; Estell J; Venner C; Sandhu I; Jenner M
• Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
  Blood Volume: 131 Page(s): 855 - 863
  02/22/2018 Authors: Chen C; Siegel D; Gutierrez M; Jacoby M; Hofmeister CC; Gabrail N; Baz R; Mau-Sorensen M; Berdeja JG; Savona M
• Importin- and exportin-5 are strong biomarkers of productive reoviral infection of cancer cells.
  Ann Diagn Pathol Volume: 32 Page(s): 28 - 34
  02/01/2018 Authors: Nuovo G; Tran H; Gutierrez A; Fadda P; Pichiorri F; Caserta E; Hofmeister CC; Chesi M; Leif Bergsagel P; Morris D
• Daratumumab induces CD38 internalization and impairs myeloma cell adhesion.
  Oncoimmunology Volume: 7 Page(s): e1486948
  01/01/2018 Authors: Ghose J; Viola D; Terrazas C; Caserta E; Troadec E; Khalife J; Gunes EG; Sanchez J; McDonald T; Marcucci G
• NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.
  J Natl Compr Canc Netw Volume: 16 Page(s): 11 - 20
  01/01/2018 Authors: Kumar SK; Callander NS; Alsina M; Atanackovic D; Biermann JS; Castillo J; Chandler JC; Costello C; Faiman M; Fung HC
• Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity
  Volume: 130
  12/07/2017 Authors: Wall SA; Zhao Q; Ranganathan P; Elder P; William BM; Puto M; Roddy J; Klisovic RB; Blum W; Benson DM
• B-Cell Lymphoma Patients Have a 10% Risk of Shingles, 7% in Cutaneous T-Cell Lymphoma
  Volume: 130
  12/07/2017 Authors: Hussaini SB; Hussaini SB; Chu J; Williams N; Sharma N; Benson DM; Rosko AE; Efebera YA; Hofmeister CC
• Immunomodulatory Effects of HDACi in Combination with Checkpoint Blockade and Lenalidomide in the Immunosuppressive Multiple Myeloma Bone Marrow Microenvironment
  Volume: 130
  12/07/2017 Authors: Whitehill GD; Chivers A; Danielson B; Tessier JSR; Duran GH; Bender GL; Sborov DW; Hofmeister CC; Bradner J; Hideshima T
• Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab
  Volume: 130
  12/07/2017 Authors: Vaughn JL; Zhao Q; Ranganathan P; Elder P; William BM; Puto M; Roddy J; Klisovic R; Blum W; Benson DM
• Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
  Leukemia Volume: 31 Page(s): 2695 - 2701
  12/01/2017 Authors: Richardson PG; Hofmeister CC; Raje NS; Siegel DS; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J
• G-CSF improves safety when you start the day after autologous transplant in multiple myeloma.
  Leuk Lymphoma Volume: 58 Page(s): 2947 - 2951
  12/01/2017 Authors: Sborov DW; Cho YK; Cottini F; Hade EM; Lamprecht M; Tackett K; Sharma N; Williams N; Li J; Devine S
• A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.
  Leuk Lymphoma Volume: 58 Page(s): 2310 - 2318
  10/01/2017 Authors: Sborov DW; Canella A; Hade EM; Mo X; Khountham S; Wang J; Ni W; Poi M; Coss C; Liu Z
• Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.
  Lancet Haematol Volume: 4 Page(s): e431 - e442
  09/01/2017 Authors: Holstein SA; Jung S-H; Richardson PG; Hofmeister CC; Hurd DD; Hassoun H; Giralt S; Stadtmauer EA; Weisdorf DJ; Vij R
• Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.
  Clin Pharmacol Ther Volume: 102 Page(s): 511 - 519
  09/01/2017 Authors: Cho YK; Sborov DW; Lamprecht M; Li J; Wang J; Hade EM; Gao Y; Tackett K; Williams N; Benson DM
• Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant.
  Mol Carcinog Volume: 56 Page(s): 1722 - 1732
  07/01/2017 Authors: Poi MJ; Li J; Sborov DW; VanGundy Z; Cho YK; Lamprecht M; Pichiorri F; Phelps MA; Hofmeister CC
• A potential role for NKG2A to influence post-transplant outcomes in multiple myeloma
  Volume: 77
  07/01/2017 Authors: Cooperrider J; Ciarlariello PD; Hughes T; Williams N; Hofmeister C; Baiocchi R; Benson DM
• TWICE-WEEKLY IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP DATA FOR PATIENTS WHO DID NOT UNDERGO STEM CELL TRANSPLANTATION
  Volume: 102 Page(s): 317 - 318
  06/26/2017 Authors: Richardson P; Hofmeister C; Rosenbaum C; Htut M; Vesole D; Berdeja J; Liedtke M; Chari A; Smith S; Lebovic D
• EFFICACY OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR THE TREATMENT OF MULTIPLE MYELOMA IN HIV-POSITIVE PATIENTS - A CASE-SERIES
  Volume: 102 Page(s): 793 - 794
  06/26/2017 Authors: Ni B; Rosko A; Benson D; Devine S; Hofmeister C; Efebera Y
• Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.
  Mol Ther Oncolytics Volume: 5 Page(s): 87 - 96
  06/16/2017 Authors: Jaime-Ramirez AC; Yu J-G; Caserta E; Yoo JY; Zhang J; Lee TJ; Hofmeister C; Lee JH; Kumar B; Pan Q
• Autologous stem cell transplant (ASCT) in myeloma to improve patient reported physical function and fatigue.
  Volume: 35
  05/20/2017 Authors: Bhatt G; Benson DM; Efebera YA; Hofmeister CC; Jaglowski SM; Devine SM; Wildes TM; Huang Y; Jones D; Rosko AE
• In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation (vol 210, pg 951, 2013)
  JOURNAL OF EXPERIMENTAL MEDICINE Volume: 214 Page(s): 1556 - 1556
  05/01/2017 Authors: Pichiorri F; Palmieri D; De Luca L; Consiglio J; You J; Rocci A; Talabere T; Piovan C; Lagana A; Cascione L
• Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.
  J Exp Med Volume: 214 Page(s): 1557
  05/01/2017 Authors: Pichiorri F; Palmieri D; De Luca L; Consiglio J; You J; Rocci A; Talabere T; Piovan C; Lagana A; Cascione L
• Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
  J Natl Compr Canc Netw Volume: 15 Page(s): 230 - 269
  02/01/2017 Authors: Kumar SK; Callander NS; Alsina M; Atanackovic D; Biermann JS; Chandler JC; Costello C; Faiman M; Fung HC; Gasparetto C
• Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions.
  Appl Immunohistochem Mol Morphol Volume: 25 Page(s): 100 - 109
  02/01/2017 Authors: Mezache L; Magro C; Hofmeister C; Pichiorri F; Sborov D; Nuovo GJ
• Once-weekly ofatumumab in untreated or relapsed Waldenstrm's macroglobulinaemia: an open-label, single-arm, phase 2 study.
  Lancet Haematol Volume: 4 Page(s): e24 - e34
  01/01/2017 Authors: Furman RR; Eradat HA; DiRienzo CG; Hofmeister CC; Hayman SR; Leonard JP; Coleman M; Advani R; Chanan-Khan A; Switzky J
• How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma.
  J Clin Oncol Volume: 34 Page(s): 4421 - 4430
  12/20/2016 Authors: Hofmeister CC; Lonial S
• Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation
  Volume: 128
  12/02/2016 Authors: Auletta JJ; Ardura MI; Vasu S; Huang Y; Zhao Q; Ruppert AS; Shoben A; Elder P; Bingman A; Kitzler R
• G-CSF Starting Day+1 after Autologous Transplant Is Safer Than Day+5 or Day+7 in Patients with Multiple Myeloma
  Volume: 128
  12/02/2016 Authors: Cottini F; Sborov D; Cho YK; Lamprecht M; Tackett K; Li J; Devine SM; Poi M; Phelps MA; Hofmeister CC
• Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy.
  Bone Marrow Transplant Volume: 51 Page(s): 1241 - 1244
  09/01/2016 Authors: Vasu S; Wu H; Satoskar A; Puto M; Roddy J; Blum W; Klisovic R; Andritsos L; Hofmeister C; Benson DM
• A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.
  Br J Haematol Volume: 174 Page(s): 323 - 325
  07/01/2016 Authors: Rosenthal A; Kumar S; Hofmeister C; Laubach J; Vij R; Dueck A; Gano K; Stewart AK
• Erratum to "Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease" [Biol Blood Marrow Transplant 22(2016):658-668].
  Biol Blood Marrow Transplant Volume: 22 Page(s): 1341
  07/01/2016 Authors: Vasu S; Geyer S; Bingman A; Auletta JJ; Jaglowski S; Elder P; O'Donnell LC; Bradbury H; Kitzler R; Andritsos L
• Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
  Blood Volume: 127 Page(s): 2693 - 2700
  06/02/2016 Authors: Richardson PG; Zimmerman TM; Hofmeister CC; Talpaz M; Chanan-Khan AA; Kaufman JL; Laubach JP; Chauhan D; Jakubowiak AJ; Reich S
• POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE IN PROTEASOME INHIBITOR-EXPOSED AND LENALIDOMIDE-REFRACTORY MYELOMA: RESULTS OF A MULTICENTER, DOSE-ESCALATION, PHASE 1 TRIAL (MM-005)
  Volume: 101 Page(s): 257 - 257
  06/01/2016 Authors: Richardson PG; Hofmeister CC; Raje NS; Siegel DS; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J
• A PHASE IB STUDY OF THE AKT INHIBITOR AFURESERTIB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS WITH LONG TERM FOLLOW-UP
  Volume: 101 Page(s): 82 - 82
  06/01/2016 Authors: Trudel S; Spencer A; Sutherland H; O'Dwyer M; Huang SY; Stewart AK; Chari A; Rosenzwieg M; Nooka A; Rosenbaum C
• A TWO-CENTER RETROSPECTIVE COMPARISON OF BEAM VS BUCYVP16 CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HODGKIN'S LYMPHOMA
  Volume: 101 Page(s): 625 - 625
  06/01/2016 Authors: Singer S; Efebera YA; Zhao Q; Abounader D; Elder P; Hofmeister CC; Benson DM; Penza S; Andritsos L; Klisovic R
• A TWO-CENTER RETROSPECTIVE COMPARISON OF BEAM VS BUCYVP16 CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA
  Volume: 101 Page(s): 625 - 626
  06/01/2016 Authors: Singer S; Efebera YA; Zhao Q; Abounader D; Elder P; Hofmeister CC; Benson DM; Penza S; Andritsos L; Klisovic R
• A feasibility study of electronic geriatric assessment for real-time morbidity evaluation.
  Volume: 34
  05/20/2016 Authors: Bhatt G; Hofmeister CC; Efebera YA; Benson DM; Sborov DW; Jaglowski SM; Devine SM; Wildes TM; Jones D; Huang Y
• A phase 1 b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).
  Volume: 34
  05/20/2016 Authors: Siegel DSD; van de Donk N; Sonneveld P; Hofmeister CC; Bahlis NJ; Niesvizky R; Sternas LA; Peluso T; Shah S; Slaughter A
• A phase 1 study of AR-42 in patients with advanced solid tumors, including nervous system tumors.
  Volume: 34
  05/20/2016 Authors: Valencia H; Newton HB; Hade E; Sborov DW; Cavaliere R; Poi M; Phelps M; Wang J; Coss CC; Khountham S
• Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.
  Mol Cancer Ther Volume: 15 Page(s): 830 - 841
  05/01/2016 Authors: Stiff A; Caserta E; Sborov DW; Nuovo GJ; Mo X; Schlotter SY; Canella A; Smith E; Badway J; Old M
• Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
  Biol Blood Marrow Transplant Volume: 22 Page(s): 658 - 668
  04/01/2016 Authors: Vasu S; Geyer S; Bingman A; Auletta JJ; Jaglowski S; Elder P; O'Donnell LC; Bradbury H; Kitzler R; Andritsos L
• NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.
  J Natl Compr Canc Netw Volume: 14 Page(s): 389 - 400
  04/01/2016 Authors: Anderson KC; Alsina M; Atanackovic D; Biermann JS; Chandler JC; Costello C; Djulbegovic B; Fung HC; Gasparetto C; Godby K
• Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.
  J Proteomics Volume: 136 Page(s): 89 - 98
  03/16/2016 Authors: Harshman SW; Canella A; Ciarlariello PD; Agarwal K; Branson OE; Rocci A; Cordero H; Phelps MA; Hade EM; Dubovsky JA
• Antithymocyte Globulin (ATG) 4.5 Vs. 6.0 Mg/Kg in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)
  Volume: 22 Page(s): S316 - S317
  03/01/2016 Authors: Issa H; Ruppert AS; Elder P; Hofmeister CC; Benson DM; Penza S; Andritsos LA; Klisovic R; Vasu S; Blum W
• Tocilizumab for steroid refractory acute graft-versus-host disease.
  Leuk Lymphoma Volume: 57 Page(s): 81 - 85
  01/01/2016 Authors: Roddy JVF; Haverkos BM; McBride A; Leininger KM; Jaglowski S; Penza S; Klisovic R; Blum W; Vasu S; Hofmeister CC
• Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).
  Biol Blood Marrow Transplant Volume: 22 Page(s): 71 - 79
  01/01/2016 Authors: Efebera YA; Geyer S; Andritsos L; Vasu S; Jaglowski S; Bingman A; Blum W; Klisovic R; Hofmeister CC; Benson DM
• Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development
  Volume: 126
  12/03/2015 Authors: Radomska H; Canella A; Jessica C; Rocci A; Luciano C; Cordero H; Joseph L; Caserta E; Ramasamy S; Efebera YA
• TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients
  Volume: 126
  12/03/2015 Authors: Hofmeister CC; Berdeja JG; Vesole DH; Suvannasankha A; Parrott T; Abonour R
• Reolysin Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients
  Volume: 126
  12/03/2015 Authors: Sborov DW; Pichiorri F; Nuovo GJ; Benson DM; Efebera YA; Rosko AE; Hofmeister CC
• Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients
  Volume: 126
  12/03/2015 Authors: Rosko AE; Hofmeister CC; Efebera YA; Benson DM; Sborov DW; Jaglowski S; Devine S; Wildes TM; Gillahan J; Jones D
• The Majority of Myeloma Patients Are Hypogonadal but This Is Not Associated with High Risk Cytogenetics
  Volume: 126
  12/03/2015 Authors: Snoad B; Hudzik S; Sborov DW; Williams N; Jones D; Hofmeister CC
• A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)
  Volume: 126
  12/03/2015 Authors: Richardson PC; Hofmeister C; Raje NS; Siegel D; Lonial S; Laubach JP; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J
• First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma
  Volume: 126
  12/03/2015 Authors: Efebera YA; Rosko AE; Hofmeister C; Benner J; Bakan C; Stamper K; Lamb T; Hollie D; Sell M; Avigan D
• Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)
  Volume: 126
  12/03/2015 Authors: Issa H; Ruppert AS; Elder P; Hofmeister C; Benson DM; Penza S; Andritsos LA; Klisovic RB; Vasu S; Blum W
• Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.
  J Natl Compr Canc Netw Volume: 13 Page(s): 1398 - 1435
  11/01/2015 Authors: Anderson KC; Alsina M; Atanackovic D; Biermann JS; Chandler JC; Costello C; Djulbegovic B; Fung HC; Gasparetto C; Godby K
• HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
  Oncotarget Volume: 6 Page(s): 31134 - 31150
  10/13/2015 Authors: Canella A; Cordero Nieves H; Sborov DW; Cascione L; Radomska HS; Smith E; Stiff A; Consiglio J; Caserta E; Rizzotto L
• Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma.
  Br J Haematol Volume: 171 Page(s): 74 - 83
  10/01/2015 Authors: Sborov DW; Benson DM; Williams N; Huang Y; Bowers MA; Humphries K; Efebera Y; Devine S; Hofmeister CC
• Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma.
  Bone Marrow Transplant Volume: 50 Page(s): 1379 - 1381
  10/01/2015 Authors: Rosko A; Hofmeister C; Benson D; Efebera Y; Huang Y; Gillahan J; Byrd JC; Burd CE
• A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
  Clin Cancer Res Volume: 21 Page(s): 4055 - 4061
  09/15/2015 Authors: Benson DM; Cohen AD; Jagannath S; Munshi NC; Spitzer G; Hofmeister CC; Efebera YA; Andre P; Zerbib R; Caligiuri MA
• ADDITIONAL PROGNOSTIC VALUE OF CIRCULATING MIR-16 EXPRESSION OVER THE USUAL PROGNOSTIC PARAMETERS IN MULTIPLE MYELOMA PATIENTS
  Volume: 100 Page(s): 176 - 176
  06/01/2015 Authors: Rocci A; Hofmeister C; Gambella M; Passera R; Stiff A; Bringhen S; Cascione L; De Luca L; Benson D; Efebera Y
• A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma.
  Volume: 33
  05/20/2015 Authors: Zonder JA; Raje NS; Scott EC; Hofmeister CC; Lendvai N; Anderson LD; Hari P; Orloff GJ; Berdeja JG; Singhal S
• Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.
  Leuk Lymphoma Volume: 56 Page(s): 1058 - 1065
  04/01/2015 Authors: Salem G; Ruppert AS; Elder P; Hofmeister CC; Benson DM; Penza S; Andritsos L; Klisovic R; Vasu S; Blum W
• A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.
  Leuk Lymphoma Volume: 56 Page(s): 1043 - 1049
  04/01/2015 Authors: Hofmeister CC; Williams N; Geyer S; Hade EM; Bowers MA; Earl CT; Vaughn J; Bingman A; Humphries K; Lozanski G
• Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT)
  Volume: 50 Page(s): S397 - S398
  03/01/2015 Authors: Efebera YA; Geyer S; Bingman A; Elder P; Kitzler R; Coombes K; Hennelly C; Cortright K; Andritsos L; Jaglowski S
• A Potential Role for Auto-Graft Immune Cell Subsets to Influence Post-Transplant Outcomes in Multiple Myeloma
  Volume: 21 Page(s): S131 - S131
  02/01/2015 Authors: Cooperrider JH; Ciarlariello D; Hughes T; Williams N; Hofmeister CC; Benson DM
• Clinically Available Genomic Testing to Improve Myeloma Care
  Volume: 20 Page(s): S3 - S3
  01/01/2015 Authors: Hofmeister C
• Development of a Predictive Pharmacokinetic and Pharmacodynamic Model to Personalize Melphalan Dosing in Autologous Transplant for Patients with Multiple Myeloma
  Volume: 124
  12/06/2014 Authors: Kyoung Y; Li J; Sborov DW; Wang J; Gao Y; Lamprecht M; Poi M; Phelps MA; Hofmeister CC
• Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT)
  Volume: 124
  12/06/2014 Authors: Efebera YA; Geyer S; Bingman A; Elder P; Kitzler R; Coombes K; Hennelly C; Cortright K; Andritsos LA; Jaglowski SM
• Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation
  Volume: 124
  12/06/2014 Authors: Vasu S; Bingman A; Geyer S; Elder P; Kitzler R; Bradbury H; Odonnell L; Blum W; Jaglowski SM; Andritsos LA
• 2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial
  Volume: 124
  12/06/2014 Authors: Sborov DW; Lamprecht M; Benson D; Tackett K; Efebera YA; Ashley RE; Devine SM; Poi M; Phelps MA; Hofmeister CC
• T-Cell p16(INK4A) Expression Increases Post-Transplant in Patients with Multiple Myeloma
  Volume: 124
  12/06/2014 Authors: Rosko AE; Hofmeister CC; Benson D; Efebera YA; Huang Y; Burd C
• Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)
  Volume: 124
  12/06/2014 Authors: Efebera YA; Geyer S; Bingman A; Kitzler R; Elder P; Andritsos LA; Jaglowski SM; Vasu S; Blum W; Klisovic RB
• A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.
  Clin Cancer Res Volume: 20 Page(s): 5946 - 5955
  12/01/2014 Authors: Sborov DW; Nuovo GJ; Stiff A; Mace T; Lesinski GB; Benson DM; Efebera YA; Rosko AE; Pichiorri F; Grever MR
• The potential of miRNAs as biomarkers for multiple myeloma.
  Expert Rev Mol Diagn Volume: 14 Page(s): 947 - 959
  11/01/2014 Authors: Rocci A; Hofmeister CC; Pichiorri F
• Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study.
  Support Care Cancer Volume: 22 Page(s): 2911 - 2916
  11/01/2014 Authors: Bechtel T; McBride A; Crawford B; Bullington S; Hofmeister CC; Benson DM; Jaglowski S; Penza S; Andritsos LA; Devine SM
• The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma.
  Bone Marrow Transplant Volume: 49 Page(s): 1323 - 1329
  10/01/2014 Authors: Jaglowski SM; Ruppert AS; Hofmeister CC; Elder P; Blum W; Klisovic R; Vasu S; Penza S; Efebera YA; Benson DM
• Molecular and immunological correlates of latent versus productive reoviral infection in cancers
  Volume: 74
  10/01/2014 Authors: Mansfield J; Stuff A; Coffey M; Nuovo G; Picchiori F; Hofmeister CC
• Circulating miRNA markers show promise as new prognosticators for multiple myeloma.
  Leukemia Volume: 28 Page(s): 1922 - 1926
  09/01/2014 Authors: Rocci A; Hofmeister CC; Geyer S; Stiff A; Gambella M; Cascione L; Guan J; Benson DM; Efebera YA; Talabere T
• Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.
  Clin Cancer Res Volume: 20 Page(s): 3989 - 4000
  08/01/2014 Authors: Chu J; He S; Deng Y; Zhang J; Peng Y; Hughes T; Yi L; Kwon C-H; Wang Q-E; Devine SM
• Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.
  Br J Cancer Volume: 111 Page(s): 272 - 280
  07/15/2014 Authors: Patnaik A; Weiss GJ; Papadopoulos KP; Hofmeister CC; Tibes R; Tolcher A; Isaacs R; Jac J; Han M; Payumo FC
• Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred.
  Amyloid Volume: 21 Page(s): 110 - 112
  06/01/2014 Authors: Efebera YA; Sturm A; Baack EC; Hofmeister CC; Satoskar A; Nadasdy T; Nadasdy G; Benson DM; Gillmore JD; Hawkins PN
• ORAL INVESTIGATIONAL PROTEASOME INHIBITOR IXAZOMIB CITRATE (MLN9708) PLUS LENALIDOMIDE-DEXAMETHASONE IN ELDERLY PATIENTS (PTS) WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA
  Volume: 99 Page(s): 106 - 106
  06/01/2014 Authors: Richardson PG; Rosenbaum CA; Hofmeister CC; Htut M; Vesole DH; Berdeja JG; Liedtke M; Chari A; Smith SD; Lebovic D
• MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.
  Volume: 32
  05/20/2014 Authors: Richardson PG; Hofmeister C; Raje NS; Siegel DSD; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J
• CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.
  Leukemia Volume: 28 Page(s): 917 - 927
  04/01/2014 Authors: Chu J; Deng Y; Benson DM; He S; Hughes T; Zhang J; Peng Y; Mao H; Yi L; Ghoshal K
• Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
  Blood Volume: 123 Page(s): 1826 - 1832
  03/20/2014 Authors: Richardson PG; Siegel DS; Vij R; Hofmeister CC; Baz R; Jagannath S; Chen C; Lonial S; Jakubowiak A; Bahlis N
• FLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome.
  Biol Blood Marrow Transplant Volume: 20 Page(s): 309 - 313
  03/01/2014 Authors: He S; Chu J; Vasu S; Deng Y; Yuan S; Zhang J; Fan Z; Hofmeister CC; He X; Marsh HC
• PHARMACOKINETICS AND PHARMACODYNAMICS OF HIGH DOSE MELPHALAN IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT.
  Volume: 95 Page(s): S38 - S38
  03/01/2014 Authors: Cho Y; Wang J; Gao Y; Li J; Lamprecht M; Jukich M; Schaaf LJ; Poi M; Hofmeister CC; Phelps MA
• NONLINEAR MIXED EFFECTS MODELING AND SIMULATION FOR MELPHALAN PHARMACOKINETIC SAMPLING SCHEME OPTIMIZATION IN PATIENTS WITH MULTIPLE MYELOMA.
  Volume: 95 Page(s): S43 - S43
  03/01/2014 Authors: Gao Y; Li J; Wang J; Poi M; Li X; Lamprecht M; Jukich M; Petrovskis K; Jarjoura D; Falk W
• High-risk myeloma: when to transplant-or not.
  Semin Oncol Volume: 41 Page(s): e1 - e9
  02/01/2014 Authors: Eicher DM; Lonial S; Cavallo F; Palumbo A; Nair B; Waheed S; Hofmeister C; Rogers HJ
• Utility of CMV PCR in the Evaluation of Allograft Recipients Presenting with Diarrhea
  Volume: 20 Page(s): S250 - S251
  02/01/2014 Authors: Sborov DW; Marsh L; Yearsley M; Geyer S; Falk W; Devine SM; Hofmeister CC
• A phase I trial of flavopiridol in relapsed multiple myeloma.
  Cancer Chemother Pharmacol Volume: 73 Page(s): 249 - 257
  02/01/2014 Authors: Hofmeister CC; Poi M; Bowers MA; Zhao W; Phelps MA; Benson DM; Kraut EH; Farag S; Efebera YA; Sexton J
• Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
  Cancer Cell Volume: 25 Page(s): 91 - 101
  01/13/2014 Authors: Lohr JG; Stojanov P; Carter SL; Cruz-Gordillo P; Lawrence MS; Auclair D; Sougnez C; Knoechel B; Gould J; Saksena G
• Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.
  J Pharm Biomed Anal Volume: 88 Page(s): 262 - 268
  01/01/2014 Authors: Jiang Y; Wang J; Rozewski DM; Kolli S; Wu C-H; Chen C-S; Yang X; Hofmeister CC; Byrd JC; Johnson AJ
• Long-Term Therapy with Lenalidomide in a Patient with POEMS Syndrome.
  Eur J Case Rep Intern Med Volume: 1
  01/01/2014 Authors: Chu BF; Shana'ah A; Hofmeister CC; Benson DM; Sell M; Tucker J; Pichiorri F; Efebera YA
• Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
  Cancer Immunol Immunother Volume: 62 Page(s): 1841 - 1849
  12/01/2013 Authors: Collins SM; Bakan CE; Swartzel GD; Hofmeister CC; Efebera YA; Kwon H; Starling GC; Ciarlariello D; Bhaskar S; Briercheck EL
• Twice-Weekly Oral MLN9708 (Ixazomib Citrate), A Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data
  Volume: 122
  11/15/2013 Authors: Richardson PG; Hofmeister CC; Rosenbaum CA; Htut M; Vesole DH; Berdeja J; Liedtke M; Chari A; Smith SD; Lebovic D
• FLT3L and AMD3100 Combination Increases Hematopoietic Stem Cell Mobilization and Leads To Improved Transplantation Outcome
  Volume: 122
  11/15/2013 Authors: Shun H; Deng Y; Vasu S; Chu J; Yuan S; Zhang J; Fan Z; Hofmeister CC; He X; March H
• The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma
  Volume: 122
  11/15/2013 Authors: Harrison B; Anderson KC; Raje N; Richardson P; Warren D; Chari A; Jagannath S; La L; Berdeja J; Zimlich M
• MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)
  Volume: 122
  11/15/2013 Authors: Richardson PG; Hofmeister CC; Siegel D; Lonial S; Laubach JP; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J; Raje N
• Characterization of multiple myeloma vesicles by label-free relative quantitation.
  Proteomics Volume: 13 Page(s): 3013 - 3029
  10/01/2013 Authors: Harshman SW; Canella A; Ciarlariello PD; Rocci A; Agarwal K; Smith EM; Talabere T; Efebera YA; Hofmeister CC; Benson DM
• Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.
  Clin Pharmacokinet Volume: 52 Page(s): 705 - 712
  08/01/2013 Authors: Poi MJ; Hofmeister CC; Johnston JS; Edwards RB; Jansak BS; Lucas DM; Farag SS; Dalton JT; Devine SM; Grever MR
• Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
  Leuk Lymphoma Volume: 54 Page(s): 1658 - 1664
  08/01/2013 Authors: Dunavin NC; Wei L; Elder P; Phillips GS; Benson DM; Hofmeister CC; Penza S; Greenfield C; Rose KS; Rieser G
• THE EFFICACY AND SAFETY OF POMALIDOMIDE WITH OR WITHOUT LOW-DOSE DEXAMETHASONE IS NOT IMPACTED BY AGE IN PATIENTS WITH ADVANCED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: MM-002 SUBGROUP ANALYSIS
  Volume: 98 Page(s): 325 - 326
  06/12/2013 Authors: Jagannath S; Hofmeister C; Baz R; Siegel DS; Vij R; Chen C; Lonial S; Anderson K; Chen M; Zaki M
• SAFETY AND EFFICACY OF POMALIDOMIDE WITH OR WITHOUT LOW-DOSE DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS ENROLLED IN THE MM-002 PHASE 2 TRIAL
  Volume: 98 Page(s): 321 - 321
  06/12/2013 Authors: Richardson P; Siegel D; Vij R; Hofmeister C; Baz R; Jagannath S; Chen C; Lonial S; Jakubowiak A; Bahlis N
• MM-005: A PHASE 1 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
  Volume: 98 Page(s): 97 - 98
  06/12/2013 Authors: Richardson P; Hofmeister C; Siegel D; Lonial S; Laubach J; Efebera Y; Vesole D; Nooka A; Rosenblatt J; Raje N
• MicroRNAs activate natural killer cells through Toll-like receptor signaling.
  Blood Volume: 121 Page(s): 4663 - 4671
  06/06/2013 Authors: He S; Chu J; Wu L-C; Mao H; Peng Y; Alvarez-Breckenridge CA; Hughes T; Wei M; Zhang J; Yuan S
• Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis
  Volume: 31
  05/20/2013 Authors: Jagannath S; Hofmeister CC; Baz RC; Siegel DSD; Vij R; Chen C; Lonial S; Anderson KC; Chen M; Zaki MH
• Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial
  Volume: 31
  05/20/2013 Authors: Siegel DSD; Richardson PGG; Vij R; Hofmeister CC; Baz RC; Jagannath S; Chen C; Lonial S; Jakubowiak AJ; Bahlis NJ
• MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM)
  Volume: 31
  05/20/2013 Authors: Richardson PGG; Hofmeister CC; Siegel DSD; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J; Raje NS
• In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.
  J Exp Med Volume: 210 Page(s): 951 - 968
  05/06/2013 Authors: Pichiorri F; Palmieri D; De Luca L; Consiglio J; You J; Rocci A; Talabere T; Piovan C; Lagana A; Cascione L
• Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.
  Med Oncol Volume: 30 Page(s): 358
  03/01/2013 Authors: Clark JI; Greene JB; Lau Clark A; Dalal JS; Hofmeister CC
• Immunohistochemical Markers Indicate Transdifferentiation of Tubular Epithelial Cells into Histiocytic Cells in the Presence of Monoclonal Casts/Crystals and Myoglobin
  Volume: 93 Page(s): 392A - 392A
  02/01/2013 Authors: Ryan M; Hemminger J; Nadasdy G; Ao X; Hofmeister C; Calomeni E; Satoskar A; Brodsky S; Nadasdy T
• Improved Survival of Patients (Pts) with Acute Graft-Versus-Host Disease (aGVHD) During Recent Years: Impact of Donor and Recipient Characteristics
  Volume: 19 Page(s): S320 - S321
  02/01/2013 Authors: Cohen JB; McBride A; Geyer S; Bingman A; Elder P; Blum W; Klisovic R; Penza S; Andritsos LA; Benson DM
• Impact of Atorvastatin On Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)
  Volume: 19 Page(s): S202 - S202
  02/01/2013 Authors: Efebera Y; Geyer S; Bingman A; Kitzler R; Elder P; Hennelly C; Andritsos LA; Jaglowski S; Blum W; Klisovic R
• Autologous Hematopoietic Stem Cell Transplant (aHSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL amyloidosis)
  Volume: 19 Page(s): S186 - S186
  02/01/2013 Authors: Pandit A; Wei L; Elder P; Falk W; Sell M; Hofmeister CC; Benson DM; Penza S; Andritsos LA; Klisovic R
• Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity (RIC) Allogeneic Hematopoeitic Stem Cell Transplant (HSCT)
  Volume: 19 Page(s): S304 - S305
  02/01/2013 Authors: Salem G; Ruppert AS; Elder P; Hofmeister CC; Benson DM; Penza S; Andritsos LA; Klisovic R; Vasu S; Blum W
• A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.
  Blood Volume: 120 Page(s): 4324 - 4333
  11/22/2012 Authors: Benson DM; Hofmeister CC; Padmanabhan S; Suvannasankha A; Jagannath S; Abonour R; Bakan C; Andre P; Efebera Y; Tiollier J
• Low Testosterone Levels Are Associated with Shorter Progression Free Survival in Multiple Myeloma
  Volume: 120
  11/16/2012 Authors: McDonagh H; Falk W; Bingman A; Geyer S; Benson DM; Efebera YA; Hofmeister CC
• Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma
  Volume: 120
  11/16/2012 Authors: Hofmeister CC; Bowers MA; Bingman A; Lozanski G; Baiocchi RA; Falk W; Benson DM; Efebera YA; Humphries K; Sell M
• miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients
  Volume: 120
  11/16/2012 Authors: Stiff A; Rocci A; Hofmeister CC; Omede P; Geyer S; Bringhen S; Cascione L; Bingman A; Gambella M; Cavallo F
• Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)
  Volume: 120
  11/16/2012 Authors: Vasu S; Jaglowski SM; Geyer S; Bingman A; Elder P; Yu J; Andritsos LA; Blum W; Klisovic RB; Penza S
• Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure
  Volume: 120
  11/16/2012 Authors: Vij R; Hofmeister CC; Richardson PG; Jagannath S; Siegel DS; Baz R; Chen M; Zaki M; Larkins G; Anderson KC
• Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.
  Volume: 120
  11/16/2012 Authors: Hofmeister CC; Liu Z; Bowers MA; Porcu P; Flynn JM; Christian B; Baiocchi RA; Benson DM; Andritsos LA; Greenfield CN
• Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma.
  Volume: 12 Page(s): 325 - 329
  10/01/2012 Authors: Bruce JT; Tran JM; Phillips G; Elder P; Mastronarde JG; Devine SM; Hofmeister CC; Wood KL
• Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
  Hematol Oncol Volume: 30 Page(s): 156 - 162
  09/01/2012 Authors: Mori S; Crawford BS; Roddy JV; Phillips G; Elder P; Hofmeister CC; Efebera Y; Benson DM
• Unique pattern of renal light chain amyloid deposition with histiocytic transdifferentiation of tubular epithelial cells.
  Am J Surg Pathol Volume: 36 Page(s): 1253 - 1257
  08/01/2012 Authors: Hemminger J; Satoskar A; Brodsky SV; Calomeni E; Nadasdy GM; Kovach P; Hofmeister CC; Nadasdy T
• CIRCULATING MICRORNA IN MULTIPLE MYELOMA: DIFFERENCES WITH HEALTHY SUBJECTS AND CORRELATION WITH BIOLOGICAL PARAMETERS
  Volume: 97 Page(s): 223 - 224
  07/16/2012 Authors: Rocci A; Hofmeister C; Omede P; Geyer S; Bringhen S; Cascione L; Bingman A; Gambella M; Stiff A; Isaia G
• Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.
  Volume: 30
  05/20/2012 Authors: Dalal JS; Greene JB; Hofmeister CC; Clark AL; Clark J
• Health care costs associated with venous thromboembolism in select high-risk ambulatory solid tumor patients in the United States.
  Volume: 30
  05/20/2012 Authors: Khorana AA; Dalal M; Lin J; Connolly GC
• Lenalidomide after stem-cell transplantation for multiple myeloma.
  N Engl J Med Volume: 366 Page(s): 1770 - 1781
  05/10/2012 Authors: McCarthy PL; Owzar K; Hofmeister CC; Hurd DD; Hassoun H; Richardson PG; Giralt S; Stadtmauer EA; Weisdorf DJ; Vij R
• IMPROVING VACCINATION OF PATIENTS PRE AND POST BONE MARROW TRANSPLANT
  Volume: 18 Page(s): S380 - S380
  02/01/2012 Authors: Cooper J; Krugh D; Duda J; Roddy J; Klisovic R; Lamprecht M; Beavers-Kirby J; Hofmeister C; Dishon-Ritzert J; Devine S
• IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
  Blood Volume: 118 Page(s): 6387 - 6391
  12/08/2011 Authors: Benson DM; Bakan CE; Zhang S; Collins SM; Liang J; Srivastava S; Hofmeister CC; Efebera Y; Andre P; Romagne F
• Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.
  Hematol Oncol Volume: 29 Page(s): 202 - 210
  12/01/2011 Authors: Hamadani M; Craig M; Phillips GS; Abraham J; Tse W; Cumpston A; Gibson L; Remick SC; Bunner P; Leadmon S
• The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development
  Volume: 118 Page(s): 470 - 471
  11/18/2011 Authors: Wear SM; Richardson PG; Revta C; Vij R; Fiala M; Lonial S; Mitchell AR; Siegel DS; Aleman A; Jakubowiak AJ
• A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia
  Volume: 118 Page(s): 1581 - 1581
  11/18/2011 Authors: Furman RR; Eradat H; DiRienzo CG; Hayman SR; Hofmeister CC; Avignon NA; Leonard JP; Coleman M; Advani R; Switzky JC
• Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)
  Volume: 118 Page(s): 140 - 141
  11/18/2011 Authors: Richardson PG; Spencer A; Cannel P; Harrison SJ; Catley L; Underhill C; Zimmerman TM; Hofmeister CC; Jakubowiak AJ; Laubach JP
• Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results
  Volume: 118 Page(s): 290 - 291
  11/18/2011 Authors: Richardson PG; Siegel DS; Vij R; Hofmeister CC; Jagannath S; Chen C; Lonial S; Jakubowiak AJ; Bahlis NJ; Baz R
• Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
  J Clin Oncol Volume: 29 Page(s): 3427 - 3434
  09/01/2011 Authors: Hofmeister CC; Yang X; Pichiorri F; Chen P; Rozewski DM; Johnson AJ; Lee S; Liu Z; Garr CL; Hade EM
• Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
  Blood Volume: 118 Page(s): 535 - 543
  07/21/2011 Authors: Jakubowiak AJ; Griffith KA; Reece DE; Hofmeister CC; Lonial S; Zimmerman TM; Campagnaro EL; Schlossman RL; Laubach JP; Raje NS
• Initial genome sequencing and analysis of multiple myeloma.
  Nature Volume: 471 Page(s): 467 - 472
  03/24/2011 Authors: Chapman MA; Lawrence MS; Keats JJ; Cibulskis K; Sougnez C; Schinzel AC; Harview CL; Brunet J-P; Ahmann GJ; Adli M
• HIGHER BUSULFAN DOSE INTENSITY DOES NOT IMPROVE OUTCOMES OF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (AHCT) FOLLOWING FLUDARABINE/BUSULFAN/ATG (FBA)-BASED REDUCED TOXICITY CONDITIONING (RTC)
  Volume: 17 Page(s): S306 - S306
  02/01/2011 Authors: Hamadani M; Craig M; Abraham J; Tse W; Cumpston A; Gibson LF; Remick SC; Leadmon S; Elder P; Hofmeister C
• IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data
  Volume: 116 Page(s): 821 - 821
  11/19/2010 Authors: Benson DM; Bakan CE; Padmanaban S; Abonour R; Suvannasankha A; Jagannath S; Chari A; Clever D; Kalu C; Collins S
• Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study
  Volume: 116 Page(s): 575 - 576
  11/19/2010 Authors: Habib J; Dunavin N; Phillips G; Elder P; Tranovich M; Benson DM; Hofmeister CC; Byrd JC; Devine SM; Efebera Y
• Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial
  Volume: 116 Page(s): 806 - 806
  11/19/2010 Authors: Jakubowiak AJ; Reece DE; Hofmeister CC; Lonial S; Zimmerman TM; Campagnaro EL; Schlossman RL; Laubach JP; Raje N; Anderson TB
• Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104
  Volume: 116 Page(s): 21 - 22
  11/19/2010 Authors: McCarthy PL; Owzar K; Anderson KC; Hofmeister CC; Hurd DD; Hassoun H; Giralt S; Stadtmauer EA; Richardson PG; Weisdorf DJ
• Tablet-Based Assessment of Fatigue, Depression, and Pain In Myeloma Patients: Cohort Study of Inflammatory Cytokines and QOL Measures In the Newly Diagnosed, Patients on Lenalidomide, and Survivors.
  Volume: 116 Page(s): 1557 - 1557
  11/19/2010 Authors: Hofmeister CC; Rieser G; Bowers MA; Merritt LC; Greenfield CN; Efebera YA; Benson DM; Devine SM; de Moor JS
• Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia
  Volume: 116 Page(s): 804 - 804
  11/19/2010 Authors: Hofmeister CC; Bowers MA; Lee S; Phelps MA; Benson DM; Kraut EH; Hicks WJ; Deam D; Johnson AJ; Farag S
• Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma
  Volume: 116 Page(s): 1466 - 1467
  11/19/2010 Authors: Dunavin N; Habib J; Phillips G; Elder P; Tranovich M; Benson DM; Hofmeister CC; Byrd JC; Devine SM; Efebera Y
• A Phase II Trial of Ofatumumab In Subjects with Waldenstrom's Macroglobulinemia.
  Volume: 116 Page(s): 749 - 750
  11/19/2010 Authors: Furman RR; Eradat H; Switzky JC; Hayman SR; Hofmeister CC; Avignon NA; Leonard JP; Coleman M; Liao Q; Shah DN
• The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics
  Volume: 116 Page(s): 1555 - 1556
  11/19/2010 Authors: Wear S; Richardson PG; Revta C; Vij R; Fiala M; Lonial S; Francis D; diCapua Siegel DS; Schramm A; Jakubowiak AJ
• RETRACTED: Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development.
  Cancer Cell Volume: 18 Page(s): 367 - 381
  10/19/2010 Authors: Pichiorri F; Suh S-S; Rocci A; De Luca L; Taccioli C; Santhanam R; Zhou W; Benson DM; Hofmainster C; Alder H
• The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
  Blood Volume: 116 Page(s): 2286 - 2294
  09/30/2010 Authors: Benson DM; Bakan CE; Mishra A; Hofmeister CC; Efebera Y; Becknell B; Baiocchi RA; Zhang J; Yu J; Smith MK
• The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.
  PLoS One Volume: 5 Page(s): e10941
  06/03/2010 Authors: Lucas DM; Alinari L; West DA; Davis ME; Edwards RB; Johnson AJ; Blum KA; Hofmeister CC; Freitas MA; Parthun MR
• TTP disease course is independent of myeloma treatment and response.
  Am J Hematol Volume: 85 Page(s): 304 - 306
  04/01/2010 Authors: Hofmeister CC; Jin M; Cataland SR; Benson DM; Wu HM
• Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.
  Leuk Lymphoma Volume: 51 Page(s): 243 - 251
  02/01/2010 Authors: Benson DM; Panzner K; Hamadani M; Hofmeister CC; Bakan CE; Smith MK; Elder P; Krugh D; O'Donnell L; Devine SM
• PHASE I STUDY OF VORINOSTAT (SAHA) AFTER AUTOLOGOUS TRANSPLANT FOR PATIENTS WITH HIGH RISK LYMPHOMA
  Volume: 16 Page(s): S204 - S205
  02/01/2010 Authors: Hofmeister CC; Lozanski G; Baiocchi RA; Hade EM; Benson DM; Blum K; Porcu P; Byrd JC; Devine SM
• Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
  Mayo Clin Proc Volume: 85 Page(s): 197 - 199
  02/01/2010 Authors: Fonseca R; Richardson P; Giralt S; Lonial S; Rajkumar SV; Stewart AK; Bensinger W; Somlo G; Vescio R; Mikhael J
• Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma
  Volume: 114 Page(s): 1126 - 1126
  11/20/2009 Authors: Hofmeister CC; Benson D; Efebera YA; Farag S; Grever MR
• Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM)
  Volume: 114 Page(s): 179 - 179
  11/20/2009 Authors: Richardson P; Hofmeister C; Jakubowiak A; Zimmerman TM; Spear MA; Palladino MA; Longenecker AM; Kelly SL; Neuteboom S; Cropp GF
• p53-Inducible Micrornas 192 and 215 Regulate p53 Expression and IGF1 Axis in Multiple Myeloma
  Volume: 114 Page(s): 781 - 781
  11/20/2009 Authors: Pichiorri F; Suh S-S; De Luca L; Taccioli C; Benson D; Hofmeister C; Aqeilan R; Croce CM
• Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial
  Volume: 114 Page(s): 60 - 60
  11/20/2009 Authors: Jakubowiak AJ; Reece DE; Hofmeister CC; Lonial S; Zimmerman TM; Campagnaro EL; Schlossman RL; Laubach J; Raje N; Anderson T
• Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results
  Volume: 114 Page(s): 1125 - 1125
  11/20/2009 Authors: Benson D; Hofmeister CC; Padmanabhan S; Abonour R; Suvannasankha A; Mita A; Squiban P; Smith MK; Bakan CE; Marzetto M
• Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events
  Volume: 114 Page(s): 1327 - 1327
  11/20/2009 Authors: McCarthy PL; Owzar K; Stadtmauer EA; Giralt S; Hurd DD; Hassoun H; Hofmeister C; Richardson P; Weisdorf DJ; Pasquini MC
• IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect
  Volume: 114 Page(s): 1489 - 1489
  11/20/2009 Authors: Benson D; Bakan CE; Zhang S; Alghothani L; Liang J; Hofmeister C; Srivastava S; Smith MK; Greenfield CN; Andre P
• Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
  Biol Blood Marrow Transplant Volume: 15 Page(s): 1422 - 1430
  11/01/2009 Authors: Hamadani M; Blum W; Phillips G; Elder P; Andritsos L; Hofmeister C; O'Donnell L; Klisovic R; Penza S; Garzon R
• Phase I adjuvant radiation with docetaxel in high-risk head and neck cancer.
  Am J Clin Oncol Volume: 32 Page(s): 396 - 400
  08/01/2009 Authors: Clark JI; Eisner RM; Hofmeister C; Norton J; Thomas S; Choudhury A; Petruzzelli G; Lathers D; Young MRI; Lau A
• Novel monoclonal antibody that enhances natural killer (NK) cell cytotoxicity against multiple myeloma (MM): Preclinical data and interim phase I clinical trial results
  Volume: 27
  05/20/2009 Authors: Benson DM; Romagne F; Squiban P; Wagtmann N; Farag S; Mita A; Hofmeister C; Smith M; Bakan C; Caligiuri M
• Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM)
  Volume: 27
  05/20/2009 Authors: Hofmeister CC; Richardson P; Zimmerman T; Spear MA; Palladino MA; Longenecker AM; Cropp GF; Lloyd GK; Hannah AL; Anderson K
• Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.
  Biol Blood Marrow Transplant Volume: 15 Page(s): 547 - 553
  05/01/2009 Authors: Hamadani M; Benson DM; Hofmeister CC; Elder P; Blum W; Porcu P; Garzon R; Blum KA; Lin TS; Marcucci G
• Regulation of expression of multiple miRNAs defines the cellular response to non genotoxic p53 activation in multiple myeloma cells
  Volume: 69
  05/01/2009 Authors: Pichiorri F; Sung-Suk S; Taccioli C; Hofmeister C; Benson D; Kuehl M; Munker R; Huebner K; Ageilan RI; Croce CM
• CD138-Selected Myeloma FISH Panel Is a Sensitive Indicator of Minimal Residual Disease and Can Reveal High-Risk DNA Mutations
  Volume: 9 Page(s): S77 - S77
  02/01/2009 Authors: Hofmeister CC; Scheier B; Benson D; Heerema D
• EVALUATION OF RABBIT ANTITHYMOCYTE GLOBULIN (RATG) DOSE-INTENSITY IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION (ASCT) FOLLOWING REDUCED INTENSITY CONDITIONING (RIC) WITH FLUDARABINE, BUSULFAN AND RATG (FBA)
  Volume: 15 Page(s): 5 - 5
  02/01/2009 Authors: Hamadani M; Benson DM; Porcu P; Elder P; Andritsos L; Hofmeister CC; Krugh D; Garzon R; Lin T; Marcucci G
• PRE-MOBILIZATION BONE MARROW PLASMACYTOSIS PREDICTS SUCCESSFUL STEM CELL MOBILIZATION IN PATIENTS WITH MULTIPLE MYELOMA RECEIVING LENALIDOMIDE-BASED INDUCTION REGIMENS
  Volume: 15 Page(s): 67 - 68
  02/01/2009 Authors: Benson DM; Hofmeister CC; Hamadani M; Panzner K; Smith MK; Penza SL; Elder P; Krugh D; O'Donnell L; Devine SM
• Allogeneic Stem Cell Transplantation for Patients with Chemo-Refractory or Progressive Aggressive Non-Hodgkin's Lymphomas
  Volume: 112 Page(s): 1121 - 1121
  11/16/2008 Authors: Hamadani M; Blum KA; Elder P; Lin TS; Porcu P; Hofmeister CC; Blum W; Marcucci G; Benson D; Devine S
• Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL)
  Volume: 112 Page(s): 756 - 757
  11/16/2008 Authors: Andritsos L; Hamadani M; Heerema NA; Benson D; Hofmeister CC; Blum W; Flynn J; Jones JA; Elder P; Lin TS
• Hospital Care of Pathological Vertebral Fracture (PVF) in Multiple Myeloma (MM) Patients: Burden of Illness and Patterns of Care
  Volume: 112 Page(s): 840 - 840
  11/16/2008 Authors: Jones JA; Byrd JC; Flynn JM; Hofmeister C
• Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma.
  Volume: 112 Page(s): 955 - 956
  11/16/2008 Authors: Richardson P; Hofmeister CC; Zimmerman TM; Chanan-Khan AA; Spear MA; Palladino MA; Longenecker AM; Cropp G; Lloyd GK; Wear S
• Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.
  Ther Drug Monit Volume: 30 Page(s): 620 - 627
  10/01/2008 Authors: Liu Q; Farley KL; Johnson AJ; Muthusamy N; Hofmeister CC; Blum KA; Schaaf LJ; Grever MR; Byrd JC; Dalton JT
• Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma.
  Leuk Res Volume: 32 Page(s): 1295 - 1298
  08/01/2008 Authors: Hofmeister CC; Jansak B; Denlinger N; Kraut EH; Benson DM; Farag SS
• Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.
  Biol Blood Marrow Transplant Volume: 14 Page(s): 783 - 789
  07/01/2008 Authors: Hamadani M; Hofmeister CC; Jansak B; Phillips G; Elder P; Blum W; Penza S; Lin TS; Klisovic R; Marcucci G
• The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma.
  Biol Blood Marrow Transplant Volume: 14 Page(s): 351 - 352
  03/01/2008 Authors: Hamadani M; Hade E; Benson DM; Hofmeister CC
• AN APREPITANT CONTAINING REGIMEN CONTROLS THE DELAYED NAUSEA AND VOMITING ASSOCIATED WITH HIGH-DOSE MELPHALAN FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
  Volume: 14 Page(s): 166 - 166
  02/01/2008 Authors: Bechtel TP; Crawford BS; Gordon SM; Penza S; Hofmeister C; Benson D; Devine S
• The effect of statin use at the time of autologous transplant on response and survival in patients with multiple myeloma
  Volume: 110 Page(s): 364B - 364B
  11/16/2007 Authors: Hamadani M; Hade EM; Elder P; Benson DM; Hofmeister CC
• Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR.
  Bone Marrow Transplant Volume: 39 Page(s): 249 - 251
  02/01/2007 Authors: Hamadani M; Martin LK; Benson DM; Copelan EA; Devine SM; Hofmeister CC
• Clinical utility of autopsy after hematopoietic stem cell transplantation.
  Biol Blood Marrow Transplant Volume: 13 Page(s): 26 - 30
  01/01/2007 Authors: Hofmeister CC; Marinier DE; Czerlanis C; Stiff PJ
• Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche.
  Bone Marrow Transplant Volume: 39 Page(s): 11 - 23
  01/01/2007 Authors: Hofmeister CC; Zhang J; Knight KL; Le P; Stiff PJ
• Retrospective utility of bronchoscopy after hematopoietic stem cell transplant.
  Bone Marrow Transplant Volume: 38 Page(s): 693 - 698
  11/01/2006 Authors: Hofmeister CC; Czerlanis C; Forsythe S; Stiff PJ
• Epidermal dendritic cell depletion with myeloablative conditioning that does not recover post transplant
  Volume: 12 Page(s): 52 - 52
  02/01/2006 Authors: Hofmeister CC; Peterson A; Tara K; Stiff P; Curry J; Nickoloff BJ
• Evaluation of pulmonary infiltrates in patients after stem cell transplantation.
  Hematology Volume: 10 Page(s): 469 - 481
  12/01/2005 Authors: Scaglione S; Hofmeister CC; Stiff P
• Autopsies post hematopoietic stem cell transplant: A reassessment of their role in patient management.
  Volume: 106 Page(s): 387A - 387A
  11/16/2005 Authors: Hofmeister CC; Parthasarathy M; Czerlanis C; Stiff PJ
• Mucosal protection by cytokines.
  Curr Hematol Rep Volume: 4 Page(s): 446 - 453
  11/01/2005 Authors: Hofmeister CC; Stiff PJ
• Graft-versus-host disease of the skin: life and death on the epidermal edge.
  Biol Blood Marrow Transplant Volume: 10 Page(s): 366 - 372
  06/01/2004 Authors: Hofmeister CC; Quinn A; Cooke KR; Stiff P; Nickoloff B; Ferrara JLM
• Should bronchoscopies be routinely performed for post-transplant infiltrates?
  Volume: 102 Page(s): 196A - 196A
  11/16/2003 Authors: Hofmeister CC; Forsythe S; Czerlanis C; Stiff P
• Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma.
  Cancer Volume: 92 Page(s): 2334 - 2340
  11/01/2001 Authors: Clark JI; Hofmeister C; Choudhury A; Matz G; Collins S; Bastian R; Melian E; Emami B; Petruzzelli G
• Wavelet analysis of high resolution signal-averaged electrocardiograms in postinfarction patients with bundle branch block
  Volume: 48 Page(s): 237A - 237A
  09/01/2000 Authors: Raman SV; Hofmeister C; Jagadeesh JM; Boyer KL; Nelson SD
• Wavelet analysis of SAECG to identify patients with conduction defects at risk for sudden cardiac death.
  Volume: 33 Page(s): 497 - 502
  01/01/1997 Authors: Jagadeesh JM; Hofmeister C; Nelson SD; Barria E